SG10201900451SA - Pharmaceutical formulation containing improved antibody molecules - Google Patents

Pharmaceutical formulation containing improved antibody molecules

Info

Publication number
SG10201900451SA
SG10201900451SA SG10201900451SA SG10201900451SA SG10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA SG 10201900451S A SG10201900451S A SG 10201900451SA
Authority
SG
Singapore
Prior art keywords
antibody molecules
present
pharmaceutical formulation
formulation containing
containing improved
Prior art date
Application number
SG10201900451SA
Inventor
Tomoyuki Igawa
Shinya Ishii
Atsuhiko Maeda
Mika Sakurai
Tetsuo Kojima
Tatsuhiko Tachibana
Hirotake Shiraiwa
Hiroyuki Tsunoda
Yoshinobu Higuchi
Chifumi Moriyama
Akira Hayasaka
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of SG10201900451SA publication Critical patent/SG10201900451SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

TITLE: PHARMACEUTICAL FORMULATION CONTAINING IMPROVED ANTIBODY MOLECULES An objective of the present invention is to provide pharmaceutical formulations containing improved antibody molecules. The present invention provides pharmaceutical formulations comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. Present formulations contain preferably arginine as stabilizer and are provided in liquid or solid form. Fig. 18
SG10201900451SA 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules SG10201900451SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009069095 2009-03-19

Publications (1)

Publication Number Publication Date
SG10201900451SA true SG10201900451SA (en) 2019-02-27

Family

ID=42739479

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201703707YA SG10201703707YA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG2011066768A SG174428A1 (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG10201900451SA SG10201900451SA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201703707YA SG10201703707YA (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules
SG2011066768A SG174428A1 (en) 2009-03-19 2010-03-19 Pharmaceutical formulation containing improved antibody molecules

Country Status (8)

Country Link
JP (2) JP4885308B2 (en)
KR (1) KR101468271B1 (en)
AR (1) AR075908A1 (en)
AU (1) AU2010225951B2 (en)
RU (1) RU2565809C2 (en)
SG (3) SG10201703707YA (en)
TW (1) TWI440470B (en)
WO (1) WO2010106812A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007232873B2 (en) 2006-03-31 2014-02-20 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (en) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3417B1 (en) * 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
TWI505838B (en) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody
KR20120138241A (en) 2010-03-11 2012-12-24 화이자 인코포레이티드 Antibodies with ph dependent antigen binding
KR20200059320A (en) * 2010-11-08 2020-05-28 제넨테크, 인크. Subcutaneously administered anti-il-6 receptor antibody
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP3539991A1 (en) * 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
JP6032818B2 (en) 2011-02-25 2016-11-30 中外製薬株式会社 FcγRIIb-specific Fc antibody
WO2012132067A1 (en) * 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
BR112014013081A2 (en) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha drug-containing cell vehicle for formation of an immune complex
MX2015014017A (en) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Fc region variant.
US20160340730A1 (en) * 2013-12-20 2016-11-24 Diogenix, Inc. Methods for evaluating neurological disease
AU2014370873B2 (en) * 2013-12-27 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
CN107614683B (en) * 2015-05-22 2020-12-22 安斯泰来制药株式会社 Novel anti-human NGF antibody Fab fragment
SG11201805123XA (en) 2015-12-18 2018-07-30 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
AU2017333367A1 (en) * 2016-09-27 2019-04-04 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
EP3589318A1 (en) * 2017-03-01 2020-01-08 MedImmune Limited Formulations of monoclonal antibodies
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
WO2019078344A1 (en) 2017-10-20 2019-04-25 学校法人兵庫医科大学 Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
JP2021504482A (en) * 2017-11-30 2021-02-15 バイオ−テラ ソリュ−ションズ，エルティーディー． Liquid formulation of humanized antibody for the treatment of IL-6 related diseases
JP7458790B2 (en) 2018-01-31 2024-04-01 元一 加藤 Asthma therapeutic agent containing IL-6 inhibitor
WO2020047029A1 (en) 2018-08-29 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
US11498969B2 (en) 2019-01-31 2022-11-15 Sanofi Biotechnology Compositions and methods for treating juvenile idiopathic arthritis
CA3133610A1 (en) 2019-03-29 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
WO2020213665A1 (en) 2019-04-17 2020-10-22 国立大学法人広島大学 Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
JP7466640B2 (en) 2020-05-29 2024-04-12 中外製薬株式会社 Antibody-containing formulations
KR20220028972A (en) * 2020-08-31 2022-03-08 (주)셀트리온 Stable Pharmaceutical Formulation
MX2023010491A (en) 2021-03-12 2023-09-18 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treatment or prevention of myasthenia gravis.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1060194A1 (en) * 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
CN100374457C (en) * 2001-11-14 2008-03-12 森托科尔公司 Anti-IL-6 antibodies, compositions, methods and uses
KR101080021B1 (en) * 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 Antibody-containing solution pharmaceuticals
CA2502904C (en) * 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004075913A1 (en) * 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
JP4685764B2 (en) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
BRPI0506679A (en) * 2004-02-11 2007-05-15 Warner Lambert Co Methods of Treating Osteoarthritis with IL-6 Antagonists
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
AU2007232873B2 (en) * 2006-03-31 2014-02-20 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
BRPI0712224B8 (en) * 2006-06-02 2021-05-25 Regeneron Pharma high affinity antibodies to the human IL-6 receptor and pharmaceutical compositions
PE20091205A1 (en) * 2007-09-26 2009-09-09 Chugai Pharmaceutical Co Ltd IL-6 ANTI-RECEPTOR ANTIBODY
KR101680906B1 (en) * 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
EP4368721A2 (en) * 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
TWI564021B (en) * 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules

Also Published As

Publication number Publication date
JP5661553B2 (en) 2015-01-28
JP2011173918A (en) 2011-09-08
KR101468271B1 (en) 2014-12-03
RU2565809C2 (en) 2015-10-20
SG10201703707YA (en) 2017-06-29
WO2010106812A1 (en) 2010-09-23
TWI440470B (en) 2014-06-11
JP2012504106A (en) 2012-02-16
TW201100100A (en) 2011-01-01
AU2010225951A1 (en) 2011-09-22
KR20110139745A (en) 2011-12-29
JP4885308B2 (en) 2012-02-29
RU2011142184A (en) 2013-04-27
SG174428A1 (en) 2011-10-28
AU2010225951B2 (en) 2014-03-13
AR075908A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
SG10201900451SA (en) Pharmaceutical formulation containing improved antibody molecules
MY153908A (en) Improved antibody molecules
NZ601114A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
GEP201706734B (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
MX2013011366A (en) Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity.
GT201200069A (en) VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS
MX2011011772A (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MX342608B (en) Virion-like delivery particles for self-replicating rna molecules.
EP3351559A3 (en) Subcutaneously administered anti-il-6 receptor antibody
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
WO2007092772A3 (en) Protein formulations
WO2013173129A3 (en) Treatment of amd using aav sflt-1
IN2014CN02591A (en)
WO2008103409A3 (en) Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis
DOP2010000379A (en) INSULIN COMPOUNDS LISPRO PEGILADA
WO2012151247A3 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
EP3207938A3 (en) Ctla-4 variants
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
EA201391786A1 (en) HALOGEN-ALKYL-1,3-OXAZINS AS BACE1 AND / OR BACE2 INHIBITORS
WO2011098518A3 (en) Delivery of immunoglobulin variable domains and constructs thereof
EA201391737A1 (en) NEW CONNECTIONS AS DIACYLGLYCEROLACILTRANSFERASE INHIBITORS
BR112014017242A2 (en) immunogenic hpv l2-containing vlps and related compositions and methods
JP2015034132A (en) Composition for external preparation